2007
DOI: 10.1038/sj.leu.2404937
|View full text |Cite
|
Sign up to set email alerts
|

Mcl-1 and anticancer vaccination: identification of an HLA-A2-restricted epitope

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2009
2009
2022
2022

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…Using the IFN-g ELISPOT we demonstrated that both hematopoetic and solid cancer patients host spontaneous T-cell responses against Mcl-1-derived peptides [42][43][44]. Thus, strong and frequent CTL responses against Mcl-1 were detected in CLL patients, melanoma patients, pancreatic cancer patients and breast cancer patients, whereas no responses could be detected in healthy individuals.…”
Section: Mcl-1mentioning
confidence: 96%
“…Using the IFN-g ELISPOT we demonstrated that both hematopoetic and solid cancer patients host spontaneous T-cell responses against Mcl-1-derived peptides [42][43][44]. Thus, strong and frequent CTL responses against Mcl-1 were detected in CLL patients, melanoma patients, pancreatic cancer patients and breast cancer patients, whereas no responses could be detected in healthy individuals.…”
Section: Mcl-1mentioning
confidence: 96%
“…We used peptide-loaded dendritic cell (DC) from a homozygous A/A donor to stimulate autologous peripheral blood mononuclear cell (PBMC) for cloning and establishment of a cytotoxic T lymphocyte (CTL) clone specific for the HER2_P peptide as described earlier. 8 This clone (HER2_P#3) was used to show specific cytotoxic activity against the HER2_P peptide loaded to T2 cells, and importantly, absence of recognition of the HER2_A peptide (Figure 2a). The HLA restriction of the killing was shown by blocking by the HLA class I specific antibody W6/32 ( Figure 2a).…”
mentioning
confidence: 99%